$1,318.00
This Market Spotlight report covers the Thyroid cancer market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the thyroid cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence and five-year prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways:
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Subtypes
10 TREATMENT
10 Surgery
10 Radioactive iodine (RAI) therapy
10 Thyroid hormone therapy
10 External beam radiation therapy
11 Targeted therapy
12 EPIDEMIOLOGY
16 MARKETED DRUGS
19 PIPELINE DRUGS
23 RECENT EVENTS AND ANALYST OPINION
23 Retevmo for Thyroid Cancer (September 29, 2019)
24 Gavreto for Thyroid Cancer (June 3, 2019)
25 Gavreto for Thyroid Cancer (May 15, 2019)
28 KEY UPCOMING EVENTS
29 KEY REGULATORY EVENTS
29 NDA Submission For Blueprint Medicines’ Pralsetinib
29 Lilly Moves Ahead With Retevmo Launch In A Challenging Environment
29 Keeping Track: Year-End Submissions Rush Brings Seven Novel Agents To US FDA
30 PROBABILITY OF SUCCESS
31 LICENSING AND ASSET ACQUISITION DEALS
31 Roche Backs Blueprint’s Precision Therapy Pralsetinib To Challenge Lilly
32 REVENUE OPPORTUNITY
33 CLINICAL TRIAL LANDSCAPE
34 Sponsors by status
35 Sponsors by phase
37 BIBLIOGRAPHY
37 Prescription information
39 APPENDIX
LIST OF FIGURES
14 Figure 1: Trends in incident cases of thyroid cancer, 2017–26
19 Figure 2: Overview of pipeline drugs for thyroid cancer in the US
19 Figure 3: Pipeline drugs for thyroid cancer, by company
20 Figure 4: Pipeline drugs for thyroid cancer, by drug type
20 Figure 5: Pipeline drugs for thyroid cancer, by classification
24 Figure 6: Retevmo for Thyroid Cancer (September 29, 2019): Phase I/II – LIBRETTO-001
25 Figure 7: Gavreto for Thyroid Cancer (June 3, 2019): Phase I/II – ARROW (NSCLC, Thyroid, Solids)
27 Figure 8: Gavreto for Thyroid Cancer (May 15, 2019): Phase I/II – ARROW (NSCLC, Thyroid, Solids)
28 Figure 9: Key upcoming events in thyroid cancer
30 Figure 10: Probability of success in the solid tumors pipeline
33 Figure 11: Clinical trials in thyroid cancer
33 Figure 12: Top 10 drugs for clinical trials in thyroid cancer
34 Figure 13: Top 10 companies for clinical trials in thyroid cancer
34 Figure 14: Trial locations in thyroid cancer
35 Figure 15: Thyroid cancer trials status
36 Figure 16: Thyroid cancer sponsors, by phase
LIST OF TABLES
13 Table 1: Incident cases of thyroid cancer, 2017–26
15 Table 2: Five-year prevalent cases of thyroid cancer, 2017–26
17 Table 3: Marketed drugs for thyroid cancer
21 Table 4: Pipeline drugs for thyroid cancer in the US
23 Table 5: Retevmo for Thyroid Cancer (September 29, 2019)
24 Table 6: Gavreto for Thyroid Cancer (June 3, 2019)
26 Table 7: Gavreto for Thyroid Cancer (May 15, 2019)
32 Table 8: Historical global sales, by drug ($m), 2015–19
32 Table 9: Forecasted global sales, by drug ($m), 2020–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!